Rolltide61 said:
Seems that way based on trail results so far. It's Lily's version of Cagrilintide.
Who do I have to suck for some eloralintide
- Thread starter TopzyTirzy
- Start date
- Status
Seems that way based on trail results so far. It's Lily's version of Cagrilintide.
Absolutely no one. It was all buildup and NO delivery. I haven't been this disappointed since the first Wuthering Heights movie.Rolltide61 said:
Found a producer and got quoted: 1 gram Eloralintide raw powder: USD 5'500 ... minimum order - I think I might get a Rolex instead ;-) and look at the time flying by until it gets more affodable. ... and raw powder is less stable - meaning lasts not as long... ;-)
I got quoted 1 Gram for $1500. Which actually is not horrible. Obviously would need to find someone to lyophilize the API into powder and vials, but hey 100mg for $150 seems to be more reasonable.
Though with it being such a new compound there are many unknowns and perhaps there are more barriers to producing then us laymen think. Would also need an HPLC test to verify the purity. Wish this compound was getting as much hype as Reta.
https://www.prnewswire.com/news-rel...efficacy-in-preclinical-models-302715843.html
This compound looks interesting though, basically oral Eloralintide with similar binding affinities. Rodent studies actually look pretty promising, they recently filed for FDA approval (or whatever the first part of human research is in the US).
Small molecule drugs are also much easier to make then complex peptides, so this could be very promising. Once the patent comes out or the compound structure, im sure we will be able to get from research vendors shortly.
Though with it being such a new compound there are many unknowns and perhaps there are more barriers to producing then us laymen think. Would also need an HPLC test to verify the purity. Wish this compound was getting as much hype as Reta.
https://www.prnewswire.com/news-rel...efficacy-in-preclinical-models-302715843.html
This compound looks interesting though, basically oral Eloralintide with similar binding affinities. Rodent studies actually look pretty promising, they recently filed for FDA approval (or whatever the first part of human research is in the US).
Small molecule drugs are also much easier to make then complex peptides, so this could be very promising. Once the patent comes out or the compound structure, im sure we will be able to get from research vendors shortly.
Dr. Jinzi J. Wu, Founder, Chairman, and CEO of Ascletis, commented: "Ascletis is committed to developing treatments for patients with obesity. Therefore, we are very excited to advance the world's first oral small molecule, eloralintide-like selective amylin receptor agonist into the clinic later this year. We believe ASC39 may provide efficacy and safety similar to Eli Lilly's eloralintide, coupled with the patient convenience and commercial scalability offered by a once-daily oral small molecule drug."
Lillys got some competition haha
Attachments
Very eagerly following the discussions and info on Elora.. so promising thus far
I'm curious if Eloralintide will end up being available and manufactured for the gray market. My understanding is that in their patents, Lilly attempted to obscure the exact structure of Eloralintide to make it more difficult to copy - learning from their experience with tirz and reta. I don't think China's been all that shy about engaging in corporate espionage and I would assume that the API for clinical trials is already being manufactured in China anyway and the "recipe" could leak from there, too. Hoping this isn't as difficult to make as it sounds like at first blush - seems like this would be a killer additive to tirz or reta.
Good news!
"This is on the production schedule, expected to be ready by the end of the month" Uther
"This is on the production schedule, expected to be ready by the end of the month" Uther
Oooooooooretarequired said:
this is going to start getting good.
Ai summary of many study's. Man i'm excited for this to be grey.
Cagrilintide and Eloralintide represent two distinct approaches to amylin‑based therapy for obesity. Cagrilintide, as a non‑selective DACRA, has demonstrated clinically meaningful weight loss (11.8% at 68 weeks) and is well into Phase 3 development, both as monotherapy and in the CagriSema combination. Eloralintide, engineered for selective AMY1R agonism, has shown superior weight loss in Phase 2 (up to 20.1% at 48 weeks) with preclinical evidence of better GI tolerability and higher‑quality weight loss (fat mass preservation). The two molecules differ not only in their receptor pharmacology but also in their formulation requirements (Cagrilintide mandates low pH; Eloralintide is stable at neutral pH and room temperature) and their clinical development timelines (CagriSema is filing for approval, while eloralintide + tirzepatide is in early‑stage investigation).
Briere, D. A., Long, A., Bullock, D. M., O’Farrell, L., Bowen, B., Lansu, K., Coskun, T., Moyers, J. S., & Qu, H. (2025). 849‑P: Eloralintide (LY3841136), a Selective Amylin Mimetic, Lowered Body Weight with Improved Quality of Weight Loss and GI Tolerability in Rats Compared with Cagrilintide. Diabetes , 74
Billings, L. K., Hsia, S., Bays, H., Tidemann‑Miller, B., O’Hagan, J., Tham, L. S., Butler, A., Kazda, C., Mather, K. J., & Coskun, T. (2025). Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48‑week phase 2, multicentre, double‑blind, randomised, placebo‑controlled trial. The Lancet , 406(10520), 2631–2643.
Gu, Y.‑M., et al. (2026). Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors. Acta Pharmacologica Sinica , 47(1), 162–172.
Oliveira Carvas, A., et al. (2025). Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3. EBioMedicine , 118, 105836.
Novo Nordisk. (2025). Novo Nordisk Presents Phase 3 Data for Next‑Generation Amylin Cagrilintide.
Bhattachar, S., Tham, L. S., Tidemann‑Miller, B., et al. (2026). Eloralintide, a selective, long‑acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. Diabetes, Obesity and Metabolism , 28(4), 2651–2660.
Cagrilintide and Eloralintide represent two distinct approaches to amylin‑based therapy for obesity. Cagrilintide, as a non‑selective DACRA, has demonstrated clinically meaningful weight loss (11.8% at 68 weeks) and is well into Phase 3 development, both as monotherapy and in the CagriSema combination. Eloralintide, engineered for selective AMY1R agonism, has shown superior weight loss in Phase 2 (up to 20.1% at 48 weeks) with preclinical evidence of better GI tolerability and higher‑quality weight loss (fat mass preservation). The two molecules differ not only in their receptor pharmacology but also in their formulation requirements (Cagrilintide mandates low pH; Eloralintide is stable at neutral pH and room temperature) and their clinical development timelines (CagriSema is filing for approval, while eloralintide + tirzepatide is in early‑stage investigation).
Briere, D. A., Long, A., Bullock, D. M., O’Farrell, L., Bowen, B., Lansu, K., Coskun, T., Moyers, J. S., & Qu, H. (2025). 849‑P: Eloralintide (LY3841136), a Selective Amylin Mimetic, Lowered Body Weight with Improved Quality of Weight Loss and GI Tolerability in Rats Compared with Cagrilintide. Diabetes , 74
Billings, L. K., Hsia, S., Bays, H., Tidemann‑Miller, B., O’Hagan, J., Tham, L. S., Butler, A., Kazda, C., Mather, K. J., & Coskun, T. (2025). Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48‑week phase 2, multicentre, double‑blind, randomised, placebo‑controlled trial. The Lancet , 406(10520), 2631–2643.
Gu, Y.‑M., et al. (2026). Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors. Acta Pharmacologica Sinica , 47(1), 162–172.
Oliveira Carvas, A., et al. (2025). Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3. EBioMedicine , 118, 105836.
Novo Nordisk. (2025). Novo Nordisk Presents Phase 3 Data for Next‑Generation Amylin Cagrilintide.
Bhattachar, S., Tham, L. S., Tidemann‑Miller, B., et al. (2026). Eloralintide, a selective, long‑acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. Diabetes, Obesity and Metabolism , 28(4), 2651–2660.
A potential issue is that Uther will be the one first out of the gate. Uther's retail prices are expensive for cagri and GLPs. And my understanding is that he no longer does bulk discounts for resellers and GBs.stoked12 said:
Uther sells cagri for $150 for a 5-mg kit and $220 for a 10-mg kit. So my hope is the cost to get started with Uther's elora won't be more than $200 or so (not including MOQ and shipping), and it will eventually be available at his US warehouse (as was the case with orfo).
But with elora positioned as "cagri 2.0," up to $300 for a kit of elora seems possible, especially since Uther sells maz for $260 for a 10-mg kit. Also, it will only cost more for Uther or anyone else to have elora tested, with one quote saying $500 with Jano.
Eventually, the mg should be higher for elora's vials since the dosage is 3x as much compared to cagri:
So hopefully there will be some competition sooner than later. But no word has been given by other vendors like PGB.
I mean id pay 300 for an elora kit as long as its at least 10mg a vial, hopefully even more to reach at least 2 target doses per vial. Btw i keep hearing about Uther but have no clue what people are referring to lol.
Thanks!
Thanks!
The bigger question is, how will you test it when it's released? Jano said he doesn't have a way to test for it.
IshimaruKenta said:
I wonder what the difficulty would be since AFAIK the structure was published with the last trial results?
I thought that he had to have reference samples in order to test. There has to be a supply chain for those reference samples, and it sounds like that may not exist yet.psycho_driver said:
I believe that's true. So it'll probably take some time for him to be able to test it. I'm honestly not sure how long it took for him to be able to test Reta when it came out.V6R3W said:
So who’s going to be the first guinea pig to buy and use this shiny new pep? 
I am tempted. But the pricing is the other issue. And if it's not tested and expensive, that's a no.
- Status
